TCM
ITCI

Teza Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Teza Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,417
Closed -$234K – 777
2024
Q2 		$234K Buy
+3,417
New +$237K 0.03% 504

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Teza Capital Management's ITCI Position: Q3 2024 in Review

Teza Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 3,417 shares — an estimated $234K sold.

Teza Capital Management first reported a position in ITCI in Q2 2024 and held it in 1 quarter. The position peaked at $234K in Q2 2024. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Teza Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Teza Capital Management sold 3,417 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $234K.
  • Teza Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 1 quarter.
  • Teza Capital Management's Intra-Cellular Therapies Inc. position peaked at $234K in Q2 2024.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Teza Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.